全球轉甲狀腺素類澱粉沉積症變性治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計到 2025 年，轉甲狀腺素類澱粉沉積症治療市場規模將達到 732 萬美元，到 2034 年將達到 1,560 萬美元，2026 年至 2034 年的複合年成長率為 8.77%。

隨著人們對轉類澱粉沉積症樣變性這種罕見疾病的認知和診斷水平的提高，預計該疾病的治療市場將迎來顯著成長。轉甲狀腺素類澱粉沉積症（ATTR）是一種進行性疾病，其特徵是澱粉樣蛋白在各種組織中積聚，最終導致器官功能障礙。 ATTR 的盛行率不斷上升，尤其是在高齡化社會中，這推動了對有效治療方法的需求。隨著醫療機構致力於改善患者的治療效果和生活品質，預計 ATTR 治療市場將持續擴張。

技術創新在塑造轉甲狀腺素類澱粉沉積症變性治療市場的未來方面發揮關鍵作用。藥物研發領域的創新，包括小分子療法和基因靜默技術，正在提高旨在抑制澱粉樣蛋白沉積和控制症狀的治療效果。此外，診斷工具的進步使得疾病的早期檢測和更精準的後續觀察成為可能，為及時介入奠定了基礎。隨著製藥公司持續加大研發投入，預計轉甲狀腺素類澱粉沉積症樣變性治療市場將迎來新型治療方法和更完善的患者管理策略的廣泛應用。

此外，對以患者為中心的護理和支持的日益重視也推動了轉甲狀腺素類澱粉沉積症變性治療市場的成長。隨著患者及其家屬對疾病和可用治療方案的了解不斷加深，對能夠兼顧醫療和心理需求的綜合護理計劃的需求也日益成長。這一趨勢促使醫療服務提供者、患者權益組織和研究人員攜手合作，共同開發教育資源和支持網路，幫助患者在整個治療過程中增強自主能力。隨著市場的不斷發展，技術整合、患者參與和全面護理方法將是成功的關鍵。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 繪製滲透率和成長前景圖
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場問題
• 波特五力分析
• PESTLE分析

4. 全球轉甲狀腺素類澱粉沉積症變性治療市場（依藥物類型分類）

• 市場分析、洞察與預測
• 塔法米迪斯
• 派蒂西蘭
• 伊諾特森
• 其他

5. 全球轉甲狀腺素類澱粉沉積症變性治療市場（依疾病類型分類）

• 市場分析、洞察與預測
• 遺傳性轉甲狀腺素蛋白類澱粉沉積症
• 野生型轉甲狀腺素蛋白類澱粉沉積症

6. 全球轉甲狀腺素類澱粉沉積症治療市場（依最終用戶分類）

• 市場分析、洞察與預測
• 醫院
• 居家照護
• 專科診所
• 其他

7. 全球轉甲狀腺素類澱粉沉積症治療藥物市場（依分銷管道分類）

• 市場分析、洞察與預測
• 醫院藥房
• 網路藥房
• 零售藥房

8. 全球轉甲狀腺素類澱粉沉積症變性治療市場（按地區分類）

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商格局（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Pfizer Inc
  • AstraZeneca
  • Prothena Corporation Plc
  • Ionis Pharmaceuticals
  • Bellus Health Inc
  • Alnylam Pharmaceuticals Inc
  • Eidos Therapeutics Inc
  • Som Biotech
  • Abbvie Inc
  • Bausch Health Companies Inc
  • Bristol Myers Squibb Company GSK Plc
  • Merck KGaA
  • Sanofi

The Transthyretin Amyloidosis Treatment Market size is expected to reach USD 15.60 Million in 2034 from USD 7.32 Million (2025) growing at a CAGR of 8.77% during 2026-2034.

The Transthyretin Amyloidosis Treatment Market is poised for significant growth as awareness and diagnosis of this rare disease increase. Transthyretin amyloidosis (ATTR) is a progressive condition characterized by the accumulation of amyloid proteins in various tissues, leading to organ dysfunction. The rising prevalence of ATTR, particularly among aging populations, is driving the demand for effective treatment options. As healthcare providers seek to improve patient outcomes and quality of life, the market for ATTR treatments is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the transthyretin amyloidosis treatment market. Innovations in drug development, including small molecule therapies and gene silencing techniques, are enhancing the efficacy of treatments aimed at reducing amyloid deposits and managing symptoms. Additionally, advancements in diagnostic tools are enabling earlier detection and more accurate monitoring of the disease, which is critical for timely intervention. As pharmaceutical companies continue to invest in research and development, the transthyretin amyloidosis treatment market is likely to see increased adoption of novel therapies and improved patient management strategies.

Moreover, the growing emphasis on patient-centered care and support is influencing the transthyretin amyloidosis treatment market's growth trajectory. As patients and their families become more informed about the disease and available treatment options, there is a rising demand for comprehensive care plans that address both medical and emotional needs. This trend is driving collaboration between healthcare providers, patient advocacy groups, and researchers to develop educational resources and support networks that empower patients in their treatment journey. As the market continues to evolve, the integration of technology, patient engagement, and holistic care approaches will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Tafamidis
• Patisiran
• Inotersen
• Others

By Diseases Type

• Hereditary Transthyretin Amyloidosis
• Wild Transthyretin Amyloidosis

By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

COMPANIES PROFILED

• Pfizer Inc, AstraZeneca, Prothena Corporation plc, Ionis Pharmaceuticals, Bellus Health Inc, Alnylam Pharmaceuticals Inc, Eidos Therapeutics Inc, Som Biotech, Abbvie Inc, Bausch Health Companies Inc, Bristol Myers Squibb Company GSK Plc, Merck KGaA, Sanofi

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY DRUG TYPE 2022-2034 (USD MN and Units)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Tafamidis Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 4.3. Patisiran Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 4.4. Inotersen Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 5. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY DISEASES TYPE 2022-2034 (USD MN and Units)

• 5.1. Market Analysis, Insights and Forecast Diseases Type
• 5.2. Hereditary Transthyretin Amyloidosis Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 5.3. Wild Transthyretin Amyloidosis Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 6. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY END USER 2022-2034 (USD MN and Units)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 6.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 6.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 7. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Units)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 7.3. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 7.4. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 8. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY REGION 2022-2034(USD MN and Units)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.2.1 By Drug Type
  • 8.2.2 By Diseases Type
  • 8.2.3 By End User
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.3.1 By Drug Type
  • 8.3.2 By Diseases Type
  • 8.3.3 By End User
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.4.1 By Drug Type
  • 8.4.2 By Diseases Type
  • 8.4.3 By End User
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.5.1 By Drug Type
  • 8.5.2 By Diseases Type
  • 8.5.3 By End User
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.6.1 By Drug Type
  • 8.6.2 By Diseases Type
  • 8.6.3 By End User
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Pfizer Inc
  • 10.2.2 AstraZeneca
  • 10.2.3 Prothena Corporation Plc
  • 10.2.4 Ionis Pharmaceuticals
  • 10.2.5 Bellus Health Inc
  • 10.2.6 Alnylam Pharmaceuticals Inc
  • 10.2.7 Eidos Therapeutics Inc
  • 10.2.8 Som Biotech
  • 10.2.9 Abbvie Inc
  • 10.2.10 Bausch Health Companies Inc
  • 10.2.11 Bristol Myers Squibb Company GSK Plc
  • 10.2.12 Merck KGaA
  • 10.2.13 Sanofi